Main outcome, as described in review reviews: "Key end result was progression of non‐Innovative AMD to possibly Superior AMD or larger severity scores of non‐State-of-the-art AMD," evaluated each individual 6 months. 34. (Atorvastatin* or liptonorm or Atorlip or atovarol or ci981 or "CI 981" or glustar or lipibec or lipitor https://spiroj655vgr7.snack-blog.com/profile